Price: $ 1295
BMI View: Turkey's pharmaceutical market has posted nominal growth in local currency terms and stemmed the decline in US dollar terms. However, imports continued their precipitous decline year-overyear, with local drugmakers picking up the slack. Continued fiscally-conservative policies by the AKP government have held back pharmaceutical spending by the SSI and kept its growth in check, even as the SSI struggles to overcome its structural deficit. Turkey stands to lose its status as a high-growth emerging market if it maintains its regressive regulatory attitude towards the sector, having been singled out by the PhRMA and Pfizer as stifling growth and market access. Headline Expenditure Projections ? Pharmaceuticals: TRY16.39bn (US$9.11bn) in 2012 to TRY17.16bn (US$9.17bn) in 2013; +4.7% in ...
Complete report details with Table of Contents and more @ http://www.marketreportsonline.com/270330.html
No comments:
Post a Comment